[Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]].
The aim of the study was to investigate renal tolerability of a flexible increasing dose-schedule of anturan (E), dependent on basal serum creatinine values. 12 male cardiovascular elderly patients (mean age: 75 years; SD: 5.5 years) suffering from mild chronic renal failure (serum creatinine between 2.00 and 4.00 mg/100 ml) entered an open study of 2-month duration. Starting dosage was 200 mg per day; daily dosage was then increased every 4 days of 200 mg, or kept constant for another 4 days, according to each patient's renal function, up to 800 mg per day. All the patients reached the maintenance dosage of 800 mg/day in 12 days, because renal function didn't worsen. Two patients were withdrawn: one at the end of the 1st month of E therapy because of exitus due to myeloma, the other one at the 24th day of E therapy for serum creatinine increase, possibly related to ongoing therapy. Creatinine clearance significantly increased, serum creatinine and uric acid significantly decreased at the end of E therapy. The other biochemical examinations didn't change and no patient complained of any undesired effect during the whole study. The obtained results seem to prove that anturan, if an incremental dose-schedule is followed at the beginning of therapy is well tolerated even in elderly azotemic patients.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003327:Coronary Disease / Q000188:drug therapy; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism; D008297:Male; D013442:Sulfinpyrazone / Q000008:administration & dosage*
D003404:Creatinine; D013442:Sulfinpyrazone
Tollerabilità renale di uno schema posologico incrementale di Enturen nell'anziano con alterata funzionalità renale.